To our surprise, simvastatin administration at doses compatible with human patient anticholesterolemic treatment resulted in the development of prostate cancer in obese mice harboring heterozygous deletion of Pten. The increase of prostate cancer aggressiveness upon statin treatment was observed with different compounds, and both in vitro and in vivo. The gene discussed is PTEN; the disease is prostate carcinoma.